ImmuCell Corporation
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-1.0M | $-2.2M | $-5.8M | $-2.5M | $-78.3K | $-1.0M | $-1.3M | $-2.3M |
| Depreciation & Amortization | $2.8M | $2.7M | — | — | — | — | — | — |
| Depreciation | $2.7M | $2.7M | $2.7M | $2.5M | $2.4M | $2.3M | $2.2M | $1.5M |
| Amortization | $19.1K | $19.1K | $19.1K | $19.1K | $19.1K | $19.1K | $19.1K | $19.1K |
| Stock-Based Compensation | $295.9K | $325.6K | $368.9K | $266.2K | $144.3K | $253.1K | $313.1K | $344.0K |
| Net Cash from Operating Activities | $2.5M | $357.9K | $-4.7M | $-1.5M | $954.2K | $1.3M | $233.5K | $-373.4K |
| Investing Activities | ||||||||
| Capital Expenditures | $1.3M | $465.7K | $1.9M | $4.0M | $2.6M | $4.1M | $1.4M | $2.0M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-1.2M | $-461.2K | $-1.9M | $-4.0M | $-1.6M | $-2.6M | $-3.4M | $-1.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-1.2M | $2.9M | $1.8M | $1.1M | $3.9M | $1.9M | $6.9M | $889.6K |
| Net Change in Cash | $48.6K | $2.8M | — | — | — | — | $3.8M | $-1.3M |
| Free Cash Flow | $1.2M | $-107.8K | $-6.6M | $-5.5M | $-1.7M | $-2.8M | $-1.2M | $-2.4M |